{"id":6823,"date":"2022-03-07T00:18:00","date_gmt":"2022-03-07T00:18:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3682682_CN82682_0"},"modified":"2022-03-07T00:18:00","modified_gmt":"2022-03-07T00:18:00","slug":"kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=6823","title":{"rendered":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients"},"content":{"rendered":"<p>SUZHOU, <span class=\"xn-location\">China<\/span>, <span class=\"xn-chron\">March 7, 2022<\/span> \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited (&#8220;Kintor Pharma&#8221;, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 (&#8220;pyrilutamide&#8221;) in <span class=\"xn-location\">China<\/span> for the treatment of female androgenetic alopecia (AGA) on&nbsp;4&nbsp;March&nbsp;2022, which has only taken around four months since its launch.<\/p>\n<p>The population of those who suffer from hair loss has a large number and tends to be younger, and&nbsp;hair&nbsp;loss is gradually becoming the focus of the whole society. By the end of 2020, the number of hair loss in <span class=\"xn-location\">China<\/span> had exceeded 252 million. AGA, known as the most common type of hair loss, is a condition that can affect both men and women. In <span class=\"xn-location\">China<\/span>, the prevalence of AGA is approximately 21.3% in males and 6.0% in females*.<\/p>\n<p>Dr. <span class=\"xn-person\">Youzhi Tong<\/span>, founder, Chairman, and CEO of Kintor Pharma commented, &#8220;We are delighted to see the completion of the enrollment of all subjects in the phase II clinical trial of KX-826, and I would like to give special thanks to all the investigators, subjects and my team&nbsp;who participated in this clinical trial. In <span class=\"xn-location\">China<\/span>, one in 20 female adults suffers from hair loss, and the ratio&nbsp;in male adults&nbsp;is 5:1. Hair loss has an important impact on patients&#8217; mental health and quality of life. We look forward to receiving preliminary data from this study in Q4 this year, further broadening the clinical potential of KX-826 in female AGA patients, and accelerating&nbsp;KX-826&#8217;s phase III clinical trial for male AGA patients in <span class=\"xn-location\">China<\/span>, so as to meet the treatment needs of people suffering from hair loss as soon as possible.&#8221;<\/p>\n<p>About the Trial<\/p>\n<p>The phase II trial is a randomized, double-blind, placebo-controlled, multi-regional study to evaluate the efficacy and safety of KX-826 for the treatment of AGA in adult females (N=160). The primary endpoint for the trial is the change from baseline in non-vellus target area hair counts (TAHC) at week 24. Peking University People&#8217;s Hospital leads the trial, with 15 hospitals participating in.&nbsp;Professor Zhang Jianzhong,&nbsp;director of the Department of Dermatology, Peking University People&#8217;s Hospital&nbsp;and chairman of the 13th session of the Dermatology and Venereology Branch of the Chinese Medical Association,&nbsp;is the leading principal investigator (leading PI) of the phase II clinical trial of KX-826 for female AGA patients.&nbsp;<\/p>\n<p>About KX-826<\/p>\n<p>KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. For the AGA indication, on <span class=\"xn-chron\">8 September 2021<\/span>, Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile.&nbsp;Kintor Pharma now&nbsp;is conducting a phase III clinical trial of KX-826 in <span class=\"xn-location\">China<\/span> and a phase II clinical trial of KX-826 in the US&nbsp; for male AGA patients, and conducting a phase&nbsp;II clinical trial of KX-826 for female AGA patients in China.&nbsp;For the acne vulgaris indication, Kintor Pharma is conducting a phase II clinical trial of KX-826 in <span class=\"xn-location\">China<\/span> for the treatment of acne vulgaris.<\/p>\n<p>About Kintor Pharmaceutical Limited<\/p>\n<p>Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecules and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia, and acne. For more information, visit&nbsp;www.kintor.com.cn.<\/p>\n<p>* Guidelines for the diagnosis and treatment of androgenetic&nbsp;alopecia in <span class=\"xn-location\">China<\/span><\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN82682&amp;sd=2022-03-06\"> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients-301496366.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients-301496366.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SUZHOU, China, March 7, 2022 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited (&#8220;Kintor Pharma&#8221;, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 (&#8220;pyrilutamide&#8221;) in China for the treatment of female androgenetic alopecia [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":6824,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-6823","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=6823\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients - My Blog\" \/>\n<meta property=\"og:description\" content=\"SUZHOU, China, March 7, 2022 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited (&#8220;Kintor Pharma&#8221;, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 (&#8220;pyrilutamide&#8221;) in China for the treatment of female androgenetic alopecia [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=6823\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-07T00:18:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png\" \/>\n\t<meta property=\"og:image:width\" content=\"16\" \/>\n\t<meta property=\"og:image:height\" content=\"16\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients\",\"datePublished\":\"2022-03-07T00:18:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823\"},\"wordCount\":634,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823\",\"name\":\"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png\",\"datePublished\":\"2022-03-07T00:18:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png\",\"width\":16,\"height\":16},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=6823#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=6823","og_locale":"en_US","og_type":"article","og_title":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients - My Blog","og_description":"SUZHOU, China, March 7, 2022 \/PRNewswire\/ &#8212; Kintor Pharmaceutical Limited (&#8220;Kintor Pharma&#8221;, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 (&#8220;pyrilutamide&#8221;) in China for the treatment of female androgenetic alopecia [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=6823","og_site_name":"My Blog","article_published_time":"2022-03-07T00:18:00+00:00","og_image":[{"width":16,"height":16,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png","type":"image\/png"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=6823#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6823"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients","datePublished":"2022-03-07T00:18:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6823"},"wordCount":634,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6823#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=6823","url":"https:\/\/transmediavictoria.net.au\/?p=6823","name":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6823#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6823#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png","datePublished":"2022-03-07T00:18:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=6823#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=6823"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=6823#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/03\/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients.png","width":16,"height":16},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=6823#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/6823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6823"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/6823\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/6824"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}